ORMP insider filings
ORAMED PHARMACEUTICALS INC. — 50 most recent insider filings (SEC Forms 3/4/5) from EDGAR, normalized by FilingPulse. Latest filing: 2026-11-13. Screen ORMP transaction legs live →
Insider transaction summary — last 90 days
2026-08-23 to 2026-11-21, from the filings listed below: 14 insider filings (Forms 3/4/5). Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): none reported.
- Open-market sales (code S, non-derivative): 2 legs across 2 filings by 2 insiders — 50,000 shares, $225,530 total (shares × price as filed).
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 38.
- Largest priced transaction: sale of 30,000 shares @ $4.51 ($135,330) by Hexter Joshua, filed 2026-10-02.
By insider — same window
Open-market purchase/sale legs on non-derivative securities, grouped by the filing's reporting owner(s); joint filings appear once. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Insider | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|
| Hexter Joshua — COO & CBO | 3 | — | 1 leg · 30,000 sh · $135,330 | 7 |
| Gabay Avraham — Chief Financial Officer | 3 | — | 1 leg · 20,000 sh · $90,200 | 3 |
| KIDRON NADAV — President and CEO, Director | 2 | — | — | 10 |
| Kidron Miriam — Chief Scientific Officer, Director | 2 | — | — | 10 |
| Aghion Daniel — Director | 1 | — | — | 2 |
| Mayer Arie — Director | 1 | — | — | 2 |
| Reznick Yehuda — Director | 1 | — | — | 2 |
| Shapiro Benjamin — Director | 1 | — | — | 2 |
Recent insider filings — ORAMED PHARMACEUTICALS INC.
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2026-11-13 | 4 | Shapiro Benjamin — Director | Grant/award (A): 72,780 · Grant/award (A): 1,050 | EDGAR |
| 2026-11-13 | 4 | Reznick Yehuda — Director | Grant/award (A): 72,780 · Grant/award (A): 2,890 | EDGAR |
| 2026-11-13 | 4 | Kidron Miriam — Chief Scientific Officer, Director | Grant/award (A): 357,000 · Grant/award (A): 242,000 | EDGAR |
| 2026-11-13 | 4 | Gabay Avraham — Chief Financial Officer | Grant/award (A): 357,000 · Grant/award (A): 242,000 | EDGAR |
| 2026-11-13 | 4 | Hexter Joshua — COO & CBO | Grant/award (A): 357,000 · Grant/award (A): 242,000 | EDGAR |
| 2026-11-13 | 4 | KIDRON NADAV — President and CEO, Director | Grant/award (A): 629,000 · Grant/award (A): 688,000 | EDGAR |
| 2026-11-13 | 4 | Aghion Daniel — Director | Grant/award (A): 72,780 · Grant/award (A): 2,890 | EDGAR |
| 2026-11-13 | 4 | Mayer Arie — Director | Grant/award (A): 72,780 · Grant/award (A): 1,470 | EDGAR |
| 2026-10-02 | 4 | Hexter Joshua — COO & CBO | Sale (S): 30,000 @ $4.51 | EDGAR |
| 2026-10-02 | 4 | Gabay Avraham — Chief Financial Officer | Sale (S): 20,000 @ $4.51 | EDGAR |
| 2026-09-25 | 4 | Gabay Avraham — Chief Financial Officer | Grant/award (A): 209,291 | EDGAR |
| 2026-09-25 | 4 | Kidron Miriam — Chief Scientific Officer, Director | Grant/award (A): 208,125 · Grant/award (A): 209,291 · Disposition to issuer (D): 104,000 (derivative) · Disposition to issuer (D): 100,000 (derivative) · Disposition to issuer (D): 69,999 (derivative) · Disposition to issuer (D): 47,000 (derivative) · +2 more | EDGAR |
| 2026-09-25 | 4 | Hexter Joshua — COO & CBO | Grant/award (A): 75,455 · Grant/award (A): 209,291 · Disposition to issuer (D): 50,000 (derivative) · Disposition to issuer (D): 50,000 (derivative) · Disposition to issuer (D): 36,000 (derivative) | EDGAR |
| 2026-09-25 | 4 | KIDRON NADAV — President and CEO, Director | Grant/award (A): 349,497 · Grant/award (A): 368,765 · Disposition to issuer (D): 196,500 (derivative) · Disposition to issuer (D): 190,000 (derivative) · Disposition to issuer (D): 49,000 (derivative) · Disposition to issuer (D): 97,000 (derivative) · +2 more | EDGAR |
| 2026-07-02 | 4 | Hexter Joshua — COO & CBO | Sale (S): 137,000 @ $4.46 · Option exercise (M): 50,000 @ $3.69 · Option exercise (M): 50,000 (derivative) @ $0 | EDGAR |
| 2026-07-02 | 4 | Gabay Avraham — Chief Financial Officer | Sale (S): 73,360 @ $4.51 | EDGAR |
| 2026-03-31 | 4 | KIDRON NADAV — President and CEO, Director | Tax withholding (F): 44,818 @ $3.31 | EDGAR |
| 2026-03-31 | 4 | Kidron Miriam — Chief Scientific Officer, Director | Tax withholding (F): 435,084 @ $3.31 | EDGAR |
| 2026-03-18 | 4 | Kidron Miriam — Chief Scientific Officer, Director | Grant/award (A): 119,558 @ $0 | EDGAR |
| 2026-03-18 | 4 | KIDRON NADAV — President and CEO, Director | Grant/award (A): 167,005 @ $0 | EDGAR |
| 2026-03-18 | 4 | Hexter Joshua — COO & CBO | Grant/award (A): 95,889 @ $0 | EDGAR |
| 2026-03-18 | 4 | Gabay Avraham — Chief Financial Officer | Grant/award (A): 95,889 @ $0 | EDGAR |
| 2026-03-16 | 4 | KIDRON NADAV — President and CEO, Director | Gift (G): 100,000 @ $0 | EDGAR |
| 2026-01-29 | 4 | KIDRON NADAV — President and CEO, Director | Option exercise (M): 109,000 @ $0 · Option exercise (M): 109,000 (derivative) @ $0 | EDGAR |
| 2026-01-29 | 4 | Kidron Miriam — Chief Scientific Officer, Director | Option exercise (M): 19,000 @ $0 · Option exercise (M): 19,000 (derivative) @ $0 | EDGAR |
| 2026-01-29 | 4 | Hexter Joshua — COO & CBO | Option exercise (M): 19,000 @ $0 · Option exercise (M): 19,000 (derivative) @ $0 | EDGAR |
| 2026-01-29 | 4 | Gabay Avraham — Chief Financial Officer | Option exercise (M): 19,000 @ $0 · Option exercise (M): 19,000 (derivative) @ $0 | EDGAR |
| 2026-01-21 | 4 | Kidron Miriam — Chief Scientific Officer, Director | Gift (G): 86,166 @ $0 | EDGAR |
| 2026-01-05 | 4 | Reznick Yehuda — Director | Grant/award (A): 30,000 · Grant/award (A): 6,250 | EDGAR |
| 2026-01-05 | 4 | KIDRON NADAV — President and CEO, Director | Grant/award (A): 232,640 @ $0 · Grant/award (A): 327,000 @ $0 · Grant/award (A): 109,000 (derivative) @ $0 | EDGAR |
| 2026-01-05 | 4 | Kidron Miriam — Chief Scientific Officer, Director | Grant/award (A): 121,331 @ $0 · Grant/award (A): 115,000 @ $0 · Grant/award (A): 19,000 (derivative) @ $0 | EDGAR |
| 2026-01-05 | 4 | Hexter Joshua — COO & CBO | Grant/award (A): 97,328 @ $0 · Grant/award (A): 115,000 @ $0 · Grant/award (A): 19,000 (derivative) @ $0 | EDGAR |
| 2026-01-05 | 4 | Shapiro Benjamin — Director | Grant/award (A): 30,000 · Grant/award (A): 3,500 | EDGAR |
| 2026-01-05 | 4 | Mayer Arie — Director | Grant/award (A): 30,000 · Grant/award (A): 4,900 | EDGAR |
| 2026-01-02 | 4 | Aghion Daniel — Director | Grant/award (A): 30,000 · Grant/award (A): 6,250 | EDGAR |
| 2026-01-02 | 4 | Gabay Avraham — Chief Financial Officer | Grant/award (A): 81,216 @ $0 · Grant/award (A): 115,000 @ $0 · Grant/award (A): 19,000 (derivative) @ $0 | EDGAR |
| 2025-06-09 | 4 | Mayer Arie — Director | Grant/award (A): 30,000 · Grant/award (A): 6,975 | EDGAR |
| 2025-06-09 | 4 | Aghion Daniel — Director | Grant/award (A): 30,000 · Grant/award (A): 8,371 | EDGAR |
| 2025-06-09 | 4 | Reznick Yehuda — Director | Grant/award (A): 30,000 · Grant/award (A): 8,370 | EDGAR |
| 2025-06-09 | 4 | Sank Leonard — Director | Grant/award (A): 30,000 · Grant/award (A): 6,510 | EDGAR |
| 2025-06-09 | 4 | Shapiro Benjamin — Director | Grant/award (A): 30,000 · Grant/award (A): 4,650 | EDGAR |
| 2025-02-11 | 4 | Kidron Miriam — Chief Scientific Officer, Director | Grant/award (A): 74,000 @ $0 · Grant/award (A): 52,000 @ $0 · Grant/award (A): 66,667 @ $0 | EDGAR |
| 2025-02-11 | 4 | Hexter Joshua — COO & CBO | Grant/award (A): 45,000 @ $0 · Grant/award (A): 48,500 @ $0 · Grant/award (A): 33,334 @ $0 | EDGAR |
| 2025-02-11 | 4 | KIDRON NADAV — President and CEO, Director | Grant/award (A): 141,000 @ $0 · Grant/award (A): 186,000 @ $0 · Grant/award (A): 100,000 @ $0 | EDGAR |
| 2025-02-11 | 4 | Gabay Avraham — Chief Financial Officer | Grant/award (A): 34,000 @ $0 · Grant/award (A): 42,000 @ $0 | EDGAR |
| 2025-01-06 | 4 | Kidron Miriam — Chief Scientific Officer, Director | Grant/award (A): 207,000 | EDGAR |
| 2025-01-06 | 4 | KIDRON NADAV — President and CEO, Director | Grant/award (A): 433,500 | EDGAR |
| 2025-01-06 | 4 | Gabay Avraham — Chief Financial Officer | Grant/award (A): 188,000 | EDGAR |
| 2025-01-06 | 4 | Hexter Joshua — COO & CBO | Grant/award (A): 194,500 | EDGAR |
| 2024-11-08 | 4 | Hexter Joshua — COO & CBO | Grant/award (A): 30,000 | EDGAR |
Recent 8-K events — ORAMED PHARMACEUTICALS INC.
Items classified from EDGAR index headers. Browse recent 8-K filings market-wide, by item code →
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2026-11-19 | 8-K | 8.01 — Other Events | EDGAR |
| 2026-09-17 | 8-K | 5.07 — Submission of Matters to a Vote of Security Holders | EDGAR |
| 2026-06-30 | 8-K | 5.03 — Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-03-31 | 8-K | 1.01 — Entry into a Material Definitive Agreement 2.01 — Completion of Acquisition or Disposition of Assets | EDGAR |
| 2026-02-20 | 8-K | 1.01 — Entry into a Material Definitive Agreement 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-01-14 | 8-K | 1.01 — Entry into a Material Definitive Agreement 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-01-07 | 8-K | 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-12-31 | 8-K | 8.01 — Other Events | EDGAR |
| 2025-12-31 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | EDGAR |
| 2025-11-17 | 8-K | 1.01 — Entry into a Material Definitive Agreement 3.03 — Material Modification to Rights of Security Holders 9.01 — Financial Statements and Exhibits | EDGAR |
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?ticker=ORMP returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. Get a free API key → · API docs